In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Medical Services Patients & Visitors Health Library For Medical Professionals Quality About Us PhysicianLink
Text Size:  -   +  |  Print Page  |  Email Page

Electrophysiology (EP) Research



Research is one of the components that make us unique at the Baptist Heart & Vascular Institute.  Our highly trained staff is dedicated to providing the latest innovations and newest therapies in a community-based setting.  Baptist Health Lexington is working to improve the lives of our patients with heart and vascular disease.

Below is a listing of current electrophysiology (EP) clinical trials:

 

IRB 917 MultiSENSE:
Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients (MultiSENSE)

Purpose:  The purpose of the MultiSENSE study is to collect chronic ambulatory data simultaneously from multiple sensors in CRT-D devices in order to develop algorithms for the early detection of worsening heart failure.

Eligibility: Patients who have been implanted with the Boston Scientific COGNIS CRT-D device who have experienced a heart failure event as defined by the protocol within the previous 6 months or 2 in the previous 12 months.

For additional information, please contact Melody Muir at 859-260-4484. 

 

IRB 945 Prompt:
Post-MI Remodeling Prevention Therapy

Purpose: To investigate the use of cardiac pacing as a method to prevent left ventricular dilation (a precursor for heart failure) after acute myocardial infarction in a select group of patients. The study will include market-approved Biventricular ICD devices in a new population

Eligibility: Patients who have had a severe MI in the past 10 days and do not already have an ICD implanted. 

Contact Melody Muir, RN 260-6429

  
IRB 958 RAID:
Ranolazine Implantable Cardioverter-Defibrillator Trial

Purpose:  To see how effective a drug called ranolazine is in reducing the risk of ventricular arrhythmia and death in people with implantable cardioverter-defibrillators (ICDs). This drug will be used with standard medications routinely prescribed in enrolled patients.

For additional information, please contact Melissa Shepherd at 859-260-4484.

 

IRB 993 Analyze ST:
ST Monitoring To Detect ACS Events In ICD Patients Study 

Purpose:  To demonstrate the safety and effectiveness of the ST monitoring feature.  The study will be looking at the sensitivity of the ST Monitoring feature to detect clinical event with a low rate of false alerts.  Device is designed to potentially give patients an early warning sign of a new MI.

Eligibility:  Patients who have a history of and MI or coronary artery disease and are indicated for an ICD implant or generator change-out.

Contact Melissa Shepherd, RN 260-4484

 

IRB 1050 CAP2:
Continued Access to Prevail (Watchman Left Atrial Appendage Occlusive device)

Purpose: To demonstrate the safety and effectiveness of the Watchman LAA occlusive device in patients with non-valvular AFib.  This is a device alternative to Coumadin for stroke prevention in AFib patients

Eligibility:  Patients with non-valvular atrial fibrillation with a CHADS2 score of 2 or greater and is eligible to come off of Coumadin.

Contact Melody Muir, RN 260-6429

 

IRB 1071 MultiPoint Pacing (MPP):

Purpose: A Randomized study to evaluate the safety and efficacy of patients treated with MultiPoint Pacing compared to standard Biventricular pacing.

Eligibility:  Patient eligible to receive a newly implanted BiVICD

Contact Melissa Shepherd, RN 260-4484

 

IRB 1094 reMARQable (“Remarkable”):
nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

Purpose:  To demonstrate the safety and efficacy a new pulmonary vein ablation catheter that is circular or a crescent shaped, with multi-site ablation capabilities in comparison to the traditional single site catheter currently available on the market

Eligibility: Patients with symptomatic, paroxysmal atrial fibrillation undergoing a pulmonary vein ablation procedure for the first time and have failed at least one antiarrhythmic drug.

Contact Melody Muir, RN 260-6429

 

IRB 1113 Amplatzer Cardiac Plug (ACP):

Purpose:  To evaluate the safety and efficacy of the Amplatzer Cardiac Plug Left Atrial Appendage occlusive device with non-valvular AFib.  This is a device alternative to Coumadin for stroke prevention in AFib patients

Eligibility:  Patients with non-valvular atrial fibrillation with a CHADS2 score of 2 or greater and is eligible to come off of Coumadin.

Contact Melody Muir, RN 260-6429